BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 29141850)

  • 21. Autoantibodies, antigen-autoantibody complexes and antigens complement CA125 for early detection of ovarian cancer.
    Young Han C; Bedia JS; Yang WL; Hawley SJ; Bergan L; Hopper M; Celestino J; Guo J; Gornet TG; Soosaipillai A; Yang H; Doskocil SD; Lokshin AE; Handy BC; Diamandis EP; Moore RG; Lu KH; Lu Z; Anderson KS; Drescher CW; Skates SJ; Bast RC
    Br J Cancer; 2024 Mar; 130(5):861-868. PubMed ID: 38195887
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer.
    Yu-Rice Y; Edassery SL; Urban N; Hellstrom I; Hellstrom KE; Deng Y; Li Y; Luborsky JL
    Reproduction; 2017 Mar; 153(3):277-284. PubMed ID: 27965399
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum autoantibodies against a panel of 15 tumor-associated antigens in the detection of ovarian cancer.
    Sun H; Shi JX; Zhang HF; Xing MT; Li P; Dai LP; Luo CL; Wang X; Wang P; Ye H; Li LX; Zhang JY
    Tumour Biol; 2017 Jun; 39(6):1010428317699132. PubMed ID: 28618923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer.
    Simon I; Liu Y; Krall KL; Urban N; Wolfert RL; Kim NW; McIntosh MW
    Gynecol Oncol; 2007 Jul; 106(1):112-8. PubMed ID: 17490732
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.
    Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN
    Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of serum autoantibodies against tumor-associated antigens as biomarkers in lung cancer.
    Li P; Shi JX; Xing MT; Dai LP; Li JT; Zhang JY
    Tumour Biol; 2017 Oct; 39(10):1010428317711662. PubMed ID: 29022480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mapping Epitopes Recognised by Autoantibodies Shows Potential for the Diagnosis of High-Grade Serous Ovarian Cancer and Monitoring Response to Therapy for This Malignancy.
    Moody R; Wilson K; Kampan NC; McNally OM; Jobling TW; Jaworowski A; Stephens AN; Plebanski M
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439354
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.
    Li QL; Wang CJ; Qi P; Zhang YX
    Clin Transl Oncol; 2017 Oct; 19(10):1260-1267. PubMed ID: 28444641
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LyGDI is a promising biomarker for ovarian cancer.
    Zhen H; Yang S; Wu H; Wang S; Lv J; Ma L; Zhang X
    Int J Gynecol Cancer; 2010 Apr; 20(3):316-22. PubMed ID: 20375790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer.
    Budiu RA; Mantia-Smaldone G; Elishaev E; Chu T; Thaller J; McCabe K; Lenzner D; Edwards RP; Vlad AM
    Cancer Immunol Immunother; 2011 Jul; 60(7):975-84. PubMed ID: 21461842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.
    Kadija S; Stefanovic A; Jeremic K; Radojevic MM; Nikolic L; Markovic I; Atanackovic J
    Int J Gynecol Cancer; 2012 Feb; 22(2):238-44. PubMed ID: 22214964
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum Anti-PDLIM1 Autoantibody as Diagnostic Marker in Ovarian Cancer.
    Qiu C; Duan Y; Wang B; Shi J; Wang P; Ye H; Dai L; Zhang J; Wang X
    Front Immunol; 2021; 12():698312. PubMed ID: 34489945
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of serum biomarkers for detection of early stage ovarian cancer.
    Kozak KR; Su F; Whitelegge JP; Faull K; Reddy S; Farias-Eisner R
    Proteomics; 2005 Nov; 5(17):4589-96. PubMed ID: 16237736
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Better Predictive Value of Cancer Antigen125 (CA125) as Biomarker in Ovary and Breast Tumors and its Correlation with the Histopathological Type/Grade of the Disease.
    Nazmeen A; Maiti S; Mandal K; Roy SK; Ghosh TK; Sinha NK; Mandal K
    Med Chem; 2017; 13(8):796-804. PubMed ID: 28440189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer.
    Taylor DD; Gercel-Taylor C; Parker LP
    Gynecol Oncol; 2009 Oct; 115(1):112-120. PubMed ID: 19647308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EpCAM-autoantibody levels in the course of disease of ovarian cancer patients.
    Heubner M; Errico D; Kasimir-Bauer S; Herlyn D; Kimmig R; Wimberger P
    Med Oncol; 2011 Jun; 28(2):626-30. PubMed ID: 20383668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor autoantibodies as biomarkers for predicting ovarian cancer recurrence.
    Chatterjee M; Dyson G; Levin NK; Shah JP; Morris R; Munkarah A; Tainsky MA
    Cancer Biomark; 2012; 11(2-3):59-73. PubMed ID: 23011153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The diagnostic value of determination of serum GOLPH3 associated with CA125, CA19.9 in patients with ovarian cancer.
    Fan HY; Duan DM; Liu YF
    Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4039-4044. PubMed ID: 29028099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High levels of pretreatment CA125 are associated to improved survival in high grade serous ovarian carcinoma.
    Morales-Vásquez F; Pedernera E; Reynaga-Obregón J; López-Basave HN; Gómora MJ; Carlón E; Cárdenas S; Silva-Ayala R; Almaraz M; Méndez C
    J Ovarian Res; 2016 Jul; 9(1):41. PubMed ID: 27388275
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Using protein microarray to identify and evaluate autoantibodies to tumor-associated antigens in ovarian cancer.
    Ma Y; Wang X; Qiu C; Qin J; Wang K; Sun G; Jiang D; Li J; Wang L; Shi J; Wang P; Ye H; Dai L; Jiang BH; Zhang J
    Cancer Sci; 2021 Feb; 112(2):537-549. PubMed ID: 33185955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.